Quest Diagnostics (NYSE:DGX) Price Target Raised to $250.00 at Truist Financial

Quest Diagnostics (NYSE:DGX) had its price objective lifted by Truist Financial from $225.00 to $250.00 in a report published on Friday morning,Benzinga reports. The brokerage currently has a hold rating on the medical research company’s stock.

Several other equities analysts have also issued reports on DGX. Evercore set a $225.00 price objective on Quest Diagnostics in a report on Tuesday, April 21st. Weiss Ratings raised shares of Quest Diagnostics from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, July 9th. Wall Street Zen cut Quest Diagnostics from a “buy” rating to a “hold” rating in a research report on Monday, July 20th. Jefferies Financial Group reaffirmed a “buy” rating and set a $245.00 price target on shares of Quest Diagnostics in a research note on Thursday. Finally, Robert W. Baird raised their price objective on Quest Diagnostics from $236.00 to $255.00 and gave the company a “neutral” rating in a research note on Friday. Six analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $231.73.

Quest Diagnostics Stock Performance

Shares of DGX stock opened at $228.05 on Friday. The company has a quick ratio of 1.08, a current ratio of 1.59 and a debt-to-equity ratio of 0.72. The stock has a market capitalization of $25.24 billion, a PE ratio of 24.21, a P/E/G ratio of 2.61 and a beta of 0.58. The firm has a 50 day moving average of $203.23 and a two-hundred day moving average of $197.59. Quest Diagnostics has a 52 week low of $165.78 and a 52 week high of $237.78.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $3.12 EPS for the quarter, beating analysts’ consensus estimates of $2.82 by $0.30. The company had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $2.97 billion. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.62 EPS. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. On average, research analysts predict that Quest Diagnostics will post 11.15 EPS for the current fiscal year.

Quest Diagnostics Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, July 22nd. Shareholders of record on Wednesday, July 8th were paid a dividend of $0.86 per share. The ex-dividend date was Wednesday, July 8th. This represents a $3.44 annualized dividend and a yield of 1.5%. Quest Diagnostics’s dividend payout ratio is presently 36.52%.

Insider Buying and Selling

In other news, SVP Karthik Kuppusamy sold 8,147 shares of Quest Diagnostics stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $200.00, for a total value of $1,629,400.00. Following the completion of the transaction, the senior vice president owned 13,510 shares in the company, valued at approximately $2,702,000. This trade represents a 37.62% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $194.14, for a total value of $1,941,400.00. Following the completion of the sale, the chief executive officer owned 132,423 shares of the company’s stock, valued at $25,708,601.22. This trade represents a 7.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.88% of the company’s stock.

Institutional Trading of Quest Diagnostics

Several institutional investors have recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. raised its stake in Quest Diagnostics by 346.5% during the fourth quarter. Assenagon Asset Management S.A. now owns 24,949 shares of the medical research company’s stock worth $4,329,000 after acquiring an additional 19,361 shares during the period. Davis Selected Advisers boosted its stake in Quest Diagnostics by 16.8% in the fourth quarter. Davis Selected Advisers now owns 1,589,883 shares of the medical research company’s stock valued at $275,895,000 after acquiring an additional 228,271 shares during the period. Capital Management Associates Inc acquired a new position in Quest Diagnostics in the fourth quarter valued at approximately $1,024,000. ANTIPODES PARTNERS Ltd grew its holdings in shares of Quest Diagnostics by 178.7% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 171,987 shares of the medical research company’s stock valued at $29,847,000 after purchasing an additional 110,280 shares during the last quarter. Finally, Advisors Capital Management LLC grew its holdings in shares of Quest Diagnostics by 5.4% during the fourth quarter. Advisors Capital Management LLC now owns 313,838 shares of the medical research company’s stock valued at $54,460,000 after purchasing an additional 16,194 shares during the last quarter. Institutional investors own 88.06% of the company’s stock.

Trending Headlines about Quest Diagnostics

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Quest Diagnostics posted Q2 results that beat Wall Street expectations on both revenue and earnings, helped by stronger demand for routine diagnostic and preventive testing. The company also raised its full-year 2026 outlook, which investors are reading as evidence that growth is holding up well. Article: Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
• Positive Sentiment: Mizuho raised its price target on DGX to $260 and kept an outperform rating, signaling confidence that the company can still outperform from here. Article: Quest Diagnostics price target raised by Mizuho
• Positive Sentiment: Truist also lifted its target to $250, while Robert W. Baird increased its target to $255, reflecting continued analyst optimism after the earnings beat and raised guidance. Article: Quest Diagnostics price target raised by Truist Financial Corporation
• Neutral Sentiment: Several market commentary pieces highlighted DGX as a momentum stock and noted the shares recently reached a 52-week high. That supports bullish sentiment, but these articles are mostly follow-up coverage rather than a new fundamental catalyst. Article: Are You Looking for a Top Momentum Pick? Why Quest Diagnostics (DGX) Is a Great Choice

About Quest Diagnostics

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.